Hormone replacement therapy and the risk of venous thromboembolism: A population-based study

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 5, 2010, Pages 979-986

  Renoux, C ^a   Dell'aniello, S ^a   Suissa, S ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Hormone replacement therapy; Pulmonary embolism; Tibolone; Transdermal estrogen; Venous thrombosis

Indexed keywords

ESTROGEN; GESTAGEN; TIBOLONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DATA BASE; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; FEMALE; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POPULATION RESEARCH; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM; CASE CONTROL STUDY; COHORT ANALYSIS; ESTROGEN THERAPY; MIDDLE AGED; POSTMENOPAUSE; RISK FACTOR;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 77953573349     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03839.x     Document Type: Article

References (36)

1. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996, 348:977-80.
2. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996, 348:983-7.
3. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996, 348:981-3.
4. Perez GS, Garcia Rodriguez LA, Castellsague J, Duque OA. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997, 314:796-800.
5. Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 1998, 147:387-90.
6. Hoibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism - a population-based case-control study. Thromb Haemost 1999, 82:1218-21.
7. Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, Larson EB, Rosendaal FR, Psaty BM. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004, 292:1581-7.
8. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998, 280:605-13.
9. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000, 132:689-96.
10. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy - results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000, 84:961-7.
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-33.
12. Archer DF, Hendrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, den HW, Stathopoulos V, Helmond FA. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007, 92:911-8.
13. Peverill RE. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab 2003, 17:149-64.
14. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003, 362:428-32.
15. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997, 350:1097-9.
16. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 2000, 49:591-6.
17. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R. The effects of tibolone in older postmenopausal women. N Engl J Med 2008, 359:697-708.
18. Bjarnason NH, Bjarnason K, Haarbo J, Bennink HJ, Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997, 82:1752-6.
19. Cortes-Prieto J. Coagulation and fibrinolysis in post-menopausal women treated with Org OD 14. Maturitas 1987, (Suppl. 1):67-72.
20. Parkin DE, Smith D, Al Azzawi F, Lindsay R, Hart DM. Effects of long-term Org OD 14 administration on blood coagulation in climacteric women. Maturitas 1987, 9:95-101.
21. van Wersch JW, Ubachs JM, van den Ende A, van Enk A. The effect of two regimens of hormone replacement therapy on the haemostatic profile in postmenopausal women. Eur J Clin Chem Clin Biochem 1994, 32:449-53.
22. Walker ID, Davidson JF, Richards A, Yates R, McEwan HP. The effect of the synthetic steroid Org OD14 on fibrinolysis and blood lipids in postmenopausal women. Thromb Haemost 1985, 53:303-5.
23. Winkler UH, Altkemper R, Kwee B, Helmond FA, Coelingh Bennink HJ. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 2000, 74:10-9.
24. Eilertsen AL, Qvigstad E, Andersen TO, Sandvik L, Sandset PM. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas 2006, 55:278-87.
25. Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. Thromb Res 2007, 120:371-9.
26. Renoux C, Dell'aniello S, Garbe E, Suissa S. Hormone replacement therapy use and the risk of stroke. Maturitas 2008, 61:305-9.
27. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007, 115:840-5.
28. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008, 336:1227-31.
29. Canonico M, Oger E, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006, 4:1259-65.
30. Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, henc-Gelas M, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005, 112:3495-500.
31. Hemelaar M, van der Mooren MJ, Rad M, Kluft C, Kenemans P. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril 2008, 90:642-72.
32. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004, 292:1573-80.
33. Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, Bloch MJ, Cyr MG, Gass M, Lepine L, Rodabough RJ, Sidney S, Uwaifo GI, Rosendaal FR. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006, 166:772-80.
34. Douketis JD, Julian JA, Kearon C, Anderson DR, Crowther MA, Bates SM, Barone M, Piovella F, Turpie AG, Middeldorp S, van Nguyen P, Prandoni P, Wells PS, Kovacs MJ, MacGillavry MR, Costantini L, Ginsberg JS. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost 2005, 3:943-8.
35. Farmer RD, Lawrenson RA, Todd JC, Williams TJ, MacRae KD, Tyrer F, Leydon GM. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 2000, 49:580-90.
36. Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007, 167:935-43.